2026-03-23 03:35:28
Latest Post
Kiaasa Retail Ltd opens 4 retail outlets
NIS Facility Management Services Ltd receives order worth Rs. 56.01 lakhs
IndiQube Signs 1140 Seats Workspace Leasing Deal with Major GCC Client in Pune
Thomas Cook India Ltd announces the demerger of its Resorts and Resort Management business into Sterling Holiday Resorts Ltd
Vikram Solar appoints Sameer Nagpal as CEO to Lead Next Phase of Strategic Growth
Research
IPCA Laboratories - Steady growth in export to continue - IIFL
Posted On : 2013-07-04 21:22:04( TIMEZONE : IST )
We believe export momentum will continue with pick-up in branded promotional and tender sales. Increasing capacity along with improving demand will keep Ipca's export business buoyant even in future. The fear of losing on international tender sales also has subsided with continuation of AMFM programme (affordable Medicines Facility for Malaria) over CY13-14E. The Artesunate + Amodiaquine (AS-AQ) combination drug (Rs500mn) launch is a next strong trigger in tender sales. Thus, on back of strong supplies and incremental AS-AQ combination launch, we expect the company to generate ~Rs5bn sales in FY14. We believe the Artesunate injectable (high margin and low competition) drug will prove long term growth driver with expected supplies to start by FY15. Additionally, Management expects FDA clearance of the Indore facility in 3-4 months, which will boost export; we expect full ramp-up in FY14.
Minimal near term impact of new pricing policy; longterm trend in domestic growth intact
Domestic market contributes ~30% to IPCA's total business, is expected to maintain its strong growth. Higher productivity and strong visibility is likely to spur the growth in FY14 (~18%). Ipca has one of the best franchise in domestic market. The domestic mix of drugs also bodes well with the strategy to minimize the impact by new pricing policy. Management expects to recuperate a part of the loss via price hikes in non-NLEM products. We believe some portion of the loss will also be compensated by increase in volumes of highvalue brands after price control. In domestic business, we estimate ~16% growth in FY14.
Valuations multiple to expand; recommend BUY
Ipca has a strong franchise in Indian branded business (~55% of total business) coupled with high margin exports. Management guided to 16-17% growth with stable margins in FY14. This includes continued strong guidance of 20% growth in the anti-malarial tender business for Africa (under AMFM). With multiple growth drivers for revenue and margin expansions, we believe the valuations are still attractive at 14x FY15E EPS of Rs44.8.
